- Home
- SID vs CLDX Comparison
SID vs CLDX Comparison
Compare SID & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SID
- CLDX
- Stock Information
- Founded
- SID 1941
- CLDX 1983
- Country
- SID Brazil
- CLDX United States
- Employees
- SID N/A
- CLDX N/A
- Industry
- SID Steel/Iron Ore
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SID Industrials
- CLDX Health Care
- Exchange
- SID Nasdaq
- CLDX Nasdaq
- Market Cap
- SID 1.9B
- CLDX 1.6B
- IPO Year
- SID 1997
- CLDX 2008
- Fundamental
- Price
- SID $1.39
- CLDX $24.61
- Analyst Decision
- SID Sell
- CLDX Buy
- Analyst Count
- SID 2
- CLDX 7
- Target Price
- SID $2.95
- CLDX $64.83
- AVG Volume (30 Days)
- SID 2.7M
- CLDX 1.1M
- Earning Date
- SID 03-05-2025
- CLDX 02-24-2025
- Dividend Yield
- SID 10.07%
- CLDX N/A
- EPS Growth
- SID N/A
- CLDX N/A
- EPS
- SID N/A
- CLDX N/A
- Revenue
- SID $8,019,254,042.00
- CLDX $9,976,000.00
- Revenue This Year
- SID N/A
- CLDX N/A
- Revenue Next Year
- SID $4.74
- CLDX N/A
- P/E Ratio
- SID N/A
- CLDX N/A
- Revenue Growth
- SID N/A
- CLDX 128.55
- 52 Week Low
- SID $1.27
- CLDX $22.17
- 52 Week High
- SID $3.84
- CLDX $53.18
- Technical
- Relative Strength Index (RSI)
- SID 37.14
- CLDX 46.94
- Support Level
- SID $1.27
- CLDX $22.17
- Resistance Level
- SID $1.42
- CLDX $29.05
- Average True Range (ATR)
- SID 0.06
- CLDX 1.59
- MACD
- SID 0.02
- CLDX -0.15
- Stochastic Oscillator
- SID 57.14
- CLDX 35.47
About SID Companhia Siderurgica Nacional S.A.
Companhia Siderurgica Nacional is an integrated steel producer. The company operate throughout the entire steel production chain, from the mining of iron ore to the production and sale of a diversified range of steel products. It operates in five segments namely, Steel, Mining, Logistics, Energy, and Cement. It generates maximum revenue from the steel segment. Geographically, it derives a majority of revenue from Asia.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.